Trial · NCT02257567
Results by group986
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 986
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase Ib: Percentage of Participants With Adverse Events (AEs) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | 100 | percentage of participants | ||
| Phase Ib: Percentage of Participants With Adverse Events (AEs) | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | 100 | percentage of participants | ||
| Phase Ib: Percentage of Participants With Adverse Events (AEs) | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | 100 | percentage of participants | ||
| Phase Ib: Percentage of Participants With Adverse Events (AEs) | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | 100 | percentage of participants | ||
| Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | 99.1 | percentage of participants | ||
| Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Baseline Prevalence of ADAs | 50.0 | percentage of participants | |
| Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Baseline Prevalence of ADAs | 33.3 | percentage of participants | |
| Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL | Post-Baseline Incidence of ADAs | 0 | percentage of participants | |
| Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin | Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL | Post-Baseline Incidence of ADAs | 33.3 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Baseline Prevalence of ADAs to Polatuzumab vedotin | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Baseline Prevalence of ADAs to Polatuzumab vedotin | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Post-Baseline Incidence of ADAs to Polatuzumab vedotin | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Post-Baseline Incidence of ADAs to Polatuzumab vedotin | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Baseline Prevalence of ADAs to Obinutuzumab | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Baseline Prevalence of ADAs to Obinutuzumab | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL | Post-Baseline Incidence of ADA to Obinutuzumab | 0 | percentage of participants | |
| Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab | Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL | Post-Baseline Incidence of ADA to Obinutuzumab | 0 | percentage of participants | |
| Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | Baseline Prevalence of ADAs to Polatuzumab | 0.0 | percentage of participants | |
| Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized) | Arm H (Phase II NF Cohort): Pola+BR in DLBCL | Baseline Prevalence of ADAs to Polatuzumab | 1.6 | percentage of participants | |
| Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | Post-Baseline Incidence of ADAs to Polatuzumab | 2.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02257567/results